comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 00:59:48 - browse：8853

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Chemotherapy before breast cancer surgery might fuel metastasis

WSS

Texas Medical Board asked to define abortion emergency exception

Lawmakers grill UnitedHealth CEO on Change cyberattack

Texas Medical Board asked to define abortion emergency exception

BIO to announce reorganization, senior leaders expected to depart

BIO to announce reorganization, senior leaders expected to depart

340B reform proposal comes out of Senate working group

leisure time

comprehensive

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Amgen, Regeneron, BGI Group and more

BioMarin wins approval for gene therapy to treat hemophilia A

Most antidepressants don't work on kids, teens, study finds

Hollywood unions extend contract negotiations for actors

The CDC's new social media misinformation war

How one medical school became remarkably diverse

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Walensky prepares to leave CDC — and Congress — behind

Class action alleges UnitedHealth concealed DOJ probe

focus

Novel spinal cord stimulator treats paralysis without surgery

Cano Health’s bankruptcy is a warning for Medicare Advantage

How a small hospital in rural Puerto Rico survived Hurricane Maria

Is it ever OK for doctors to lie to their patients?

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Readout Newsletter: Amgen, Regeneron, BGI Group and more

explore

leisure time

hotspot

knowledge